On November 23, 2020, Advarra announced its acquisition of Longboat, an innovative provider of clinical trial technologies focused on site training, protocol compliance, and patient engagement. You can read the full press release here.
We will continue to conduct business as usual, and clients will keep their current team for support, customer relationships, and implementation projects. Advarra clients will continue to receive the high level of quality service that they have come to expect, while gaining access to the enhanced benefits the combined company will provide.
We understand that questions may arise as we bring our organizations together, so we’ve assembled this FAQ to address some of the most commonly asked questions about the Longboat acquisition. If you don’t see your question addressed here, please contact your Longboat Team at email@example.com or the Advarra Business Development Team at firstname.lastname@example.org.
Q: How will the acquisition impact our working relationship with Longboat and Advarra?
A: Our clients and their projects remain top priority. We will maintain diligent adherence to the quality of our work, personalized client support, and turnaround times. We have assembled a dedicated team to work on integration efforts, and we will conduct business as usual and minimize any impacts to our clients. Operational excellence and ease of use will remain at the forefront of our integration efforts.
We are committed to transparency and communicating any changes as we integrate. As such, we have put together a process and communication plan for managing updates to ensure you are informed in advance of any changes.
Q: Do you plan to offer more services?
A: Empowering sites and engaging patients through technology, Longboat connects Advarra IRB and IBC reviews and consulting services to our existing site-centric technologies. We are tremendously excited about this strategic combination of Longboat and Advarra that will allow us to further develop and accelerate innovation for our technology solutions, enabling Advarra to serve our clients—life sciences companies, CROs, research sites, academic medical centers, and health systems—more comprehensively throughout their clinical trial journeys.
Q: How long do you expect integration will take?
A: The integration will progress throughout 2021. Any changes to policies and procedures that impact you will be proactively communicated.
Q: How will my interaction with Advarra and Longboat change?
A: We are committed to providing customers with the highest level of customer service. Please continue to work with your existing contacts at Longboat and Advarra. We will proactively communicate and coordinate any changes in personnel assignments in advance.
Q: What will happen to my data?
A: There will be no changes to your data or use of technology. We consider data privacy a top priority and will continue to treat your data in a protected and secure manner.
Q: Will there be any changes to existing contracts?
A: No. Advarra will continue to honor existing Longboat contracts without changes, and no changes are needed to Advarra contracts.
Q: Do you plan to merge Longboat and Advarra technology solutions?
A: We are tremendously excited to interface Advarra’s site-facing OnCore CTMS technology with Longboat’s innovative site training and patient engagement platform. Our combined capabilities will enable Advarra to offer a broader suite of solutions, driving increased efficiencies and protocol compliance in clinical trials.
Q: Is the acquisition complete?
A: Yes. Advarra’s acquisition of Longboat was completed on November 23, 2020.